Update on PEG-Interferon α-2b as Adjuvant Therapy in Melanoma

Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon α-2b (PEG-IFN) (Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2012-09, Vol.32 (9), p.3901-3909
Main Authors: DI TROLIO, Rossella, SIMEONE, Ester, DI LORENZO, Giuseppe, MARIA GRIMALDI, Antonio, ROMANO, Anna, AYALA, Fabrizio, CARACO, Corrado, MOZZILLO, Nicola, ASCIERTO, Paolo A
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Chemotherapy, Adjuvant
Dermatology
Humans
Interferon-alpha - therapeutic use
Medical sciences
Melanoma - drug therapy
Polyethylene Glycols - therapeutic use
Recombinant Proteins - therapeutic use
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon α-2b (PEG-IFN) (Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment with PEG-IFN for up to 5 years. The median recurrence-free survival of the treatment groups was significantly longer, while overall survival, a secondary endpoint, was not significantly different between the two groups. This review, after a short summary of interferon α-2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease.
ISSN:0250-7005
1791-7530